A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

• Status: Completed
• Trial end date: 2001-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of memantine, an experimental drug, in improving AIDS dementia complex (ADC).

The symptoms of ADC can be improved with zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, and the effectiveness of ZDV seems to decrease during the second and third years of therapy. The effectiveness of other antiretroviral drugs as treatment for ADC is not known, so it is important to explore alternative therapies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Memantine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV positive.

• Have been diagnosed with AIDS dementia complex (ADC).

• Have an estimated IQ of at least 70 (before the onset of ADC) or the ability to read at a 6th grade level.

• Have impaired mental skills.

• Are age18 or older.

Exclusion Criteria

You will not be eligible for this study if you:

• Have a history of a neurologic disease unrelated to HIV infection.

• Have a history of chronic seizures or head injuries.

• Have a history of central nervous system infections.

• Have certain cancers.

• Have any psychiatric illness.

• Have an active AIDS-defining opportunistic infection.

• Are pregnant or breast-feeding.